SG10201913591SA - Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins - Google Patents

Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins

Info

Publication number
SG10201913591SA
SG10201913591SA SG10201913591SA SG10201913591SA SG10201913591SA SG 10201913591S A SG10201913591S A SG 10201913591SA SG 10201913591S A SG10201913591S A SG 10201913591SA SG 10201913591S A SG10201913591S A SG 10201913591SA SG 10201913591S A SG10201913591S A SG 10201913591SA
Authority
SG
Singapore
Prior art keywords
type
compositions
methods
chimeric proteins
extracellular domains
Prior art date
Application number
SG10201913591SA
Inventor
Taylor Schreiber
George Fromm
Silva Suresh De
Neal SCHILLING
Original Assignee
Heat Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heat Biologics Inc filed Critical Heat Biologics Inc
Publication of SG10201913591SA publication Critical patent/SG10201913591SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201913591SA 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins SG10201913591SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562235727P 2015-10-01 2015-10-01
US201562263313P 2015-12-04 2015-12-04
US201662372574P 2016-08-09 2016-08-09

Publications (1)

Publication Number Publication Date
SG10201913591SA true SG10201913591SA (en) 2020-02-27

Family

ID=58424302

Family Applications (5)

Application Number Title Priority Date Filing Date
SG10201913591SA SG10201913591SA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
SG11201801984TA SG11201801984TA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
SG10201913597VA SG10201913597VA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
SG10201913573UA SG10201913573UA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
SG10201913576RA SG10201913576RA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins

Family Applications After (4)

Application Number Title Priority Date Filing Date
SG11201801984TA SG11201801984TA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
SG10201913597VA SG10201913597VA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
SG10201913573UA SG10201913573UA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
SG10201913576RA SG10201913576RA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins

Country Status (17)

Country Link
US (13) US10183060B2 (en)
EP (2) EP4183451A1 (en)
JP (3) JP6981973B2 (en)
KR (1) KR20180051651A (en)
CN (3) CN116063566A (en)
AU (3) AU2016331076B2 (en)
BR (1) BR112018006578A2 (en)
CA (1) CA2999280A1 (en)
HK (1) HK1258835A1 (en)
IL (3) IL258029B (en)
MX (2) MX2018004022A (en)
PH (1) PH12018500694A1 (en)
RU (2) RU2766200C1 (en)
SA (1) SA518391219B1 (en)
SG (5) SG10201913591SA (en)
UA (1) UA126549C2 (en)
WO (1) WO2017059168A1 (en)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US10183069B2 (en) 2011-03-21 2019-01-22 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
KR20180036974A (en) 2015-07-16 2018-04-10 바이오엑셀 테라퓨틱스 인코포레이티드 A novel approach to the treatment of cancer using immunomodulation
WO2018127916A1 (en) * 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-cd70 fusion protein and methods of use thereof
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
KR102597943B1 (en) 2017-01-05 2023-11-06 카 메디컬 리미티드 PD1-41BBL fusion protein and methods of using the same
CN110573522B (en) 2017-01-05 2023-09-19 卡尔医学有限公司 SIRP alpha-41 BBL fusion proteins and methods of use thereof
US11192933B2 (en) * 2017-02-27 2021-12-07 Shattuck Labs, Inc. VSIG8-based chimeric proteins
WO2018157162A1 (en) 2017-02-27 2018-08-30 Shattuck Labs, Inc. Tigit- and light-based chimeric proteins
BR112019017713A2 (en) 2017-02-27 2020-04-07 Shattuck Labs Inc chimeric csf1r-based proteins
CA3094886A1 (en) * 2017-03-24 2018-09-27 Orpheus Bioscience Inc. Pantids for treatment of autoimmune disorders
KR20180120893A (en) * 2017-04-28 2018-11-07 재단법인 목암생명과학연구소 Fusion protein comprising pvr and 4-1bbl, and use thereof
RU2771110C2 (en) * 2017-07-26 2022-04-26 Онкорус, Инк. Oncolytic viral vectors and their application
CN109646678A (en) * 2017-10-12 2019-04-19 中国科学院上海生命科学研究院 SUN2 albumen, its pharmaceutical applications and drug
CN108384795A (en) * 2017-10-13 2018-08-10 江苏西迪尔生物技术有限公司 Act on synthetic gene and verification method and the application of TME immune effector cells
JP7035299B2 (en) * 2017-10-26 2022-03-15 イミューンオンコ バイオファーマシューティカルズ （シャンハイ） カンパニー リミテッド New recombinant fusion proteins, as well as their preparation and use
JP7339944B2 (en) * 2017-11-07 2023-09-06 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム Methods for targeting LILRB4 using CAR-T cells or CAR-NK cells in cancer treatment
US20200407401A1 (en) * 2018-01-04 2020-12-31 Washington University Compositions and methods for inhibition of alphavirus infection
WO2019221516A1 (en) * 2018-05-16 2019-11-21 주식회사 지놈앤컴퍼니 Pharmaceutical composition for preventing or treating cancer comprising lrit2 inhibitor as active ingredient
AU2019269628A1 (en) * 2018-05-17 2020-12-03 The Board Of Trustees Of The Leland Stanford Junior University Receptor inhibition by phosphatase recruitment
AU2019290192A1 (en) 2018-06-21 2021-01-07 Shattuck Labs, Inc. Heterodimeric proteins and uses thereof
AU2019301316A1 (en) * 2018-07-11 2021-02-18 Kahr Medical Ltd. Sirpalpha-4-1BBL variant fusion protein and methods of use thereof
JP2021531265A (en) * 2018-07-11 2021-11-18 カール メディカル リミテッド PD1-4-1BBL variant fusion protein and its usage
KR20210057053A (en) 2018-08-23 2021-05-20 씨젠 인크. Anti-TIGIT antibody
US10780121B2 (en) 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
WO2020047329A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Chimeric proteins comprising extracellular domains and uses thereof
MX2021002291A (en) * 2018-08-29 2021-05-27 Shattuck Labs Inc Combination therapies comprising tim-3-based chimeric proteins.
JP2022512540A (en) * 2018-08-29 2022-02-07 シャタック ラボ，インコーポレイテッド FLT3L chimeric protein
JP2022512539A (en) * 2018-08-29 2022-02-07 シャタック ラボ，インコーポレイテッド Combination therapy
WO2020047319A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Combination therapies comprising sirp alpha-based chimeric proteins
CN109053902B (en) * 2018-09-11 2021-06-15 河南科技大学 Chimeric protein AQP4-CH2, preparation and application thereof
WO2020123477A1 (en) * 2018-12-10 2020-06-18 Bioxcel Therapeutics, Inc. Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist
BR112021012027A2 (en) * 2018-12-21 2021-11-03 Ose Immunotherapeutics Bifunctional molecule targeted against human pd-1
EP3908613A4 (en) * 2019-01-07 2022-10-19 Celluris Participações Ltda. Bispecific in tandem receptor car and method for modulating the tumoral microenvironment
CA3125474A1 (en) * 2019-01-07 2020-07-16 Shattuck Labs, Inc. Heterodimeric proteins for modulating gamma delta t cells
US11098093B2 (en) * 2019-01-07 2021-08-24 Shattuck Labs, Inc. Heterodimeric proteins for modulating gamma delta T cells
CN111606999B (en) * 2019-02-26 2022-09-06 南京惟亚德生物医药有限公司 Replicative oncolytic adenovirus with functions of activating immune co-stimulatory signaling pathway and blocking immune checkpoint and application thereof
CA3131259A1 (en) * 2019-02-28 2020-09-03 Shattuck Labs, Inc. Combination therapies
CN114126663A (en) * 2019-05-16 2022-03-01 沙塔克实验室有限公司 NK cell directed chimeric proteins
CA3144071A1 (en) * 2019-06-21 2020-12-24 Shattuck Labs, Inc. Chimeric protein expressing t-cells
EP3997114A1 (en) * 2019-07-11 2022-05-18 KAHR Medical Ltd. Heterodimers and methods of use thereof
US20220306715A1 (en) * 2019-08-30 2022-09-29 Shattuck Labs, Inc. Chimeric proteins in autoimmunity
CN112480237B (en) * 2019-09-12 2023-10-17 上海津曼特生物科技有限公司 Fusion protein and preparation method and application thereof
CN110592172B (en) * 2019-10-29 2021-05-28 华中农业大学 Method and target for screening JEV resistance gene by using CRISPR/Cas9 knockout library technology
CN110964119A (en) * 2019-12-05 2020-04-07 沣潮医药科技（上海）有限公司 Anti-malarial dimeric immunoadhesin, pharmaceutical composition and use
US20210230248A1 (en) * 2020-01-25 2021-07-29 Jun Chen Multivalent pharmacophores for high avidity and overexpressed-target specific binding and uses thereof
CN111826400A (en) * 2020-07-21 2020-10-27 中科宝承生物医学科技有限公司 Preparation method of bispecific antibody NK cell, cell and application thereof
CN111849913B (en) * 2020-07-31 2021-05-25 南京北恒生物科技有限公司 Engineered immune cells and uses thereof
US20230416333A1 (en) * 2020-10-26 2023-12-28 Shattuck Labs, Inc. Homodimeric and heterodimeric proteins comprising butyrophilin
KR102671409B1 (en) * 2021-03-02 2024-05-31 진화섭 Recombinant protein which induces cytotoxicity in CD30 expressing cell and the composition comprising the same for treating cancer
WO2022187583A1 (en) * 2021-03-05 2022-09-09 Shattuck Labs, Inc. Combination therapies with tim-3-based chimeric proteins
IL305663A (en) * 2021-03-05 2023-11-01 Shattuck Labs Inc Combination therapies with sirp alpha-based chimeric proteins
KR20220138909A (en) * 2021-04-06 2022-10-14 주식회사 이뮤노로지컬디자이닝랩 Chimeric antigen receptor specifically binding to CD47 and use thereof
WO2023004424A2 (en) * 2021-07-23 2023-01-26 University Of Southern California Genetically engineered multifunctional exosomes for immunotherapy
WO2023019251A1 (en) * 2021-08-12 2023-02-16 Baylor College Of Medicine Engineered soluble decoy receptors to enhance cancer immunotherapy
CA3242068A1 (en) * 2021-12-23 2023-06-29 Ami TAMIR Lilrb polypeptides and uses thereof
WO2023141106A2 (en) * 2022-01-20 2023-07-27 Exocure Biosciences Inc. Recombinant cell line expressing membrane proteins and vesicles prepared therefrom
WO2024006931A1 (en) * 2022-07-01 2024-01-04 Fate Therapeutics, Inc. Enhancing effector cell durability and efficacy in adoptive cell therapies
CN117886891B (en) * 2024-03-15 2024-06-07 黑龙江八一农垦大学 Polypeptide targeting macrophage CD169 receptor and application thereof

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (en) 1989-03-22 1991-07-25 Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
AU685054C (en) 1992-05-14 2003-02-27 Baylor College Of Medicine Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5674704A (en) * 1993-05-07 1997-10-07 Immunex Corporation Cytokine designated 4-IBB ligand
US6004941A (en) 1993-06-14 1999-12-21 Basf Aktiengesellschaft Methods for regulating gene expression
IT1270594B (en) 1994-07-07 1997-05-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
DE69632235T2 (en) 1995-10-18 2004-08-26 Akzo Nobel N.V. Newcastle disease viral vaccines combined
US6015709A (en) 1997-08-26 2000-01-18 Ariad Pharmaceuticals, Inc. Transcriptional activators, and compositions and uses related thereto
US5989910A (en) 1998-08-03 1999-11-23 University Of Lausanne Potent genetic switch allowing regulated gene expression in eukaryotic cells
EP1248645B1 (en) 2000-01-03 2007-04-18 Tr Associates, L.L.C. Novel chimeric proteins and their use
US20110041190A1 (en) 2002-10-31 2011-02-17 Tykocinski Mark L Novel chimeric proteins
US7696168B2 (en) 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
DK1355919T3 (en) 2000-12-12 2011-03-14 Medimmune Llc Molecules with longer half-lives, compositions and uses thereof
CA2466279A1 (en) * 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
EP1467759A4 (en) * 2002-01-30 2006-05-31 Brigham & Womens Hospital Compositions and methods related to tim-3, a th1-specific cell surface molecule
JP4685764B2 (en) * 2003-04-10 2011-05-18 アボット バイオセラピューティクス コーポレイション Modification of antibody FcRn binding affinity or serum half-life by mutagenesis
CN1902227A (en) * 2003-10-03 2007-01-24 布赖汉姆妇女医院 TIM-3 ligands and methods thereof
CN103212084B (en) * 2003-11-13 2018-07-13 韩美科学株式会社 Contain pharmaceutical composition of the immunoglobulin FC region as carrier
US7459426B2 (en) * 2004-06-04 2008-12-02 Regeneron Pharmaceuticals, Inc. Methods of using IL-1 antagonists to treat autoinflammatory disease
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
JP2006345852A (en) 2005-06-16 2006-12-28 Virxsys Corp Antibody conjugate
US8008453B2 (en) * 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
EP2027151A2 (en) 2006-05-15 2009-02-25 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
MX2008015524A (en) 2006-06-12 2009-01-13 Trubion Pharmaceuticals Inc Single-chain multivalent binding proteins with effector function.
CA2656923A1 (en) * 2006-06-21 2007-12-27 Genentech, Inc. Crystal structures of ox40l and ox40l complexed with ox40 receptor
WO2008061377A1 (en) * 2006-11-22 2008-05-29 Centre Hospitalier De L'universite De Montreal Novel receptor for cd40l and uses thereof
PT3056514T (en) 2008-01-15 2019-07-19 Univ Leland Stanford Junior Methods for manipulating phagocytosis mediated by cd47
WO2009114110A1 (en) 2008-03-08 2009-09-17 Immungene, Inc. Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
SG10201402815VA (en) * 2008-04-09 2014-09-26 Genentech Inc Novel compositions and methods for the treatment of immune related diseases
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
SG191698A1 (en) 2008-06-30 2013-07-31 Univ Pennsylvania Fn14/trail fusion proteins
KR20110044992A (en) 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 TVF-β antagonist multi-target binding protein
ES2657220T3 (en) * 2008-10-02 2018-03-02 Aptevo Research And Development Llc CD86 antagonist multi-target binding proteins
WO2010062399A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Csf1r extracellular domain fusion molecules and treatments using same
US8183207B2 (en) 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
EA201100947A1 (en) * 2008-12-19 2012-02-28 Новартис Аг SOLUBLE POLYPEPTIDES INTENDED FOR APPLICATION IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS
CN102421913A (en) 2009-03-13 2012-04-18 宾夕法尼亚大学董事会 Ox40/trail fusion proteins
CA2791383C (en) 2010-03-05 2022-09-20 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
WO2012042480A1 (en) 2010-09-28 2012-04-05 Kahr Medical Ltd. Compositions and methods for treatment of hematological malignancies
US9029315B2 (en) 2010-11-11 2015-05-12 The University Of Hong Kong Soluble PD-1 variants, fusion constructs, and uses thereof
EP3415528B1 (en) * 2011-04-13 2021-05-26 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
WO2012162565A2 (en) 2011-05-25 2012-11-29 Cel-Sci Corporation Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions
CN102850458B (en) 2011-06-28 2014-10-01 华博生物医药技术（上海）有限公司 Novel recombined dual-function fusion protein and its preparation method and application
EP2736540B1 (en) 2011-07-29 2019-03-13 The Trustees Of The University Of Pennsylvania Switch costimulatory receptors
EP2812022B1 (en) 2012-02-06 2019-06-26 Providence Health & Services - Oregon Method of monitoring cancer treatment using ox40 agonists
CA3004695C (en) * 2012-04-30 2020-08-04 Biocon Limited Targeted/immunomodulatory fusion proteins and methods for making same
HUE059815T2 (en) 2012-05-18 2022-12-28 Aptevo Res & Development Llc Bispecific scfv immunofusion (bif) binding to cd123 and cd3
MX2014014951A (en) 2012-06-06 2015-03-13 Oncomed Pharm Inc Binding agents that modulate the hippo pathway and uses thereof.
CN112587671A (en) 2012-07-18 2021-04-02 博笛生物科技有限公司 Targeted immunotherapy for cancer
ES2755156T3 (en) 2012-12-17 2020-04-21 Trillium Therapeutics Inc Treatment of diseased CD47 + cells with SIRP alpha-Fc fusions
AU2013371826A1 (en) 2013-01-01 2015-08-13 Kahr Medical Ltd. Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
US20140242077A1 (en) 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
EP2951199A4 (en) 2013-01-31 2016-07-20 Univ Jefferson Fusion proteins for modulating regulatory and effector t cells
US10533054B2 (en) 2013-01-31 2020-01-14 Thomas Jefferson University Agonist fusion protein for CD40 and OX40 and methods of stimulating the immune system
WO2014121093A1 (en) * 2013-01-31 2014-08-07 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
EP2950814A4 (en) 2013-01-31 2016-06-08 Univ Jefferson Pd-l1 and pd-l2-based fusion proteins and uses thereof
WO2015116178A1 (en) 2014-01-31 2015-08-06 Thomas Jefferson University Fusion proteins for modulating regulatory and effector t cells
CN113699114A (en) 2013-02-26 2021-11-26 纪念斯隆-凯特琳癌症中心 Compositions and methods for immunotherapy
WO2014164427A1 (en) 2013-03-12 2014-10-09 Biocon Ltd. Fusion immunomodulatory proteins and methods for making same
MX2016003292A (en) * 2013-09-13 2016-06-24 Beigene Ltd Anti-pd1 antibodies and their use as therapeutics and diagnostics.
JP2016537321A (en) * 2013-10-15 2016-12-01 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Coagulation factor VII polypeptide
US10144770B2 (en) 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
US10196435B2 (en) 2013-11-18 2019-02-05 University Of Southern California OX40L fusion protein for the immunotherapy of tumors of veterinary animals
EP3527587A1 (en) * 2013-12-17 2019-08-21 F. Hoffmann-La Roche AG Combination therapy comprising ox40 binding agonists and pd-l1 binding antagonists
CN105899535A (en) * 2013-12-17 2016-08-24 豪夫迈·罗氏有限公司 Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
AU2015205530B8 (en) 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
EP3096782A4 (en) 2014-01-21 2017-07-26 Medlmmune, LLC Compositions and methods for modulating and redirecting immune responses
GB201403875D0 (en) * 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
KR102314088B1 (en) * 2014-03-24 2021-10-15 이뮨원코 바이오파마슈티컬즈 (상하이) 컴퍼니 리미티드 Novel recombinant bi-functional fusion proteins, preparation and use thereof
BR112016027845A2 (en) 2014-05-29 2017-10-31 Medimmune Llc ox40l fusion proteins and uses thereof
EP3160497A4 (en) 2014-06-27 2018-01-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Conjugates for immunotherapy
GB2532619A (en) 2014-08-08 2016-05-25 Alexo Therapeutics Int Sirp-Alpha Variant Constructs And Uses Thereof
WO2016025385A1 (en) 2014-08-11 2016-02-18 Delinia, Inc. Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
HUE046661T2 (en) 2014-08-15 2020-03-30 Merck Patent Gmbh Sirp-alpha immunoglobulin fusion proteins
MX2017006320A (en) 2014-11-17 2017-08-10 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists.
WO2016090347A1 (en) 2014-12-05 2016-06-09 Immunext, Inc. Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
AU2015380455A1 (en) * 2015-01-26 2017-08-03 Macrogenics, Inc. Multivalent molecules comprising DR5-binding domains
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
MA41460A (en) 2015-02-03 2017-12-12 Oncomed Pharm Inc TNFRSF LIAISON AGENTS AND THEIR USES
WO2016127015A1 (en) 2015-02-06 2016-08-11 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
WO2016166139A1 (en) 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
WO2016187226A1 (en) 2015-05-18 2016-11-24 Ab Initio Biotherapeutics, Inc. Sirp polypeptide compositions and methods of use
SG10201912905VA (en) 2015-08-07 2020-02-27 Alx Oncology Inc Constructs having a sirp-alpha domain or variant thereof
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. Therapeutic cd47 antibodies

Also Published As

Publication number Publication date
US10543253B2 (en) 2020-01-28
IL295423A (en) 2022-10-01
US20180326008A1 (en) 2018-11-15
US20180326004A1 (en) 2018-11-15
US10525102B2 (en) 2020-01-07
BR112018006578A2 (en) 2018-12-26
JP2018529363A (en) 2018-10-11
SG10201913573UA (en) 2020-03-30
MX2018004022A (en) 2018-09-11
JP7303254B2 (en) 2023-07-04
US10646545B2 (en) 2020-05-12
JP6981973B2 (en) 2021-12-17
PH12018500694A1 (en) 2018-10-01
US20180326005A1 (en) 2018-11-15
AU2024202253A1 (en) 2024-05-16
US10449233B2 (en) 2019-10-22
IL303586A (en) 2023-08-01
AU2021200367B2 (en) 2024-05-02
HK1258835A1 (en) 2019-11-22
AU2016331076B2 (en) 2020-12-03
US11654180B2 (en) 2023-05-23
US10188701B2 (en) 2019-01-29
EP4183451A1 (en) 2023-05-24
EP3356393A1 (en) 2018-08-08
MX2022001299A (en) 2022-05-10
CN108350055B (en) 2022-11-08
IL295423B1 (en) 2023-07-01
RU2022102624A (en) 2022-03-10
IL258029B (en) 2022-09-01
WO2017059168A1 (en) 2017-04-06
US20180326006A1 (en) 2018-11-15
US20180326007A1 (en) 2018-11-15
SG10201913597VA (en) 2020-02-27
US10653748B2 (en) 2020-05-19
US11547742B1 (en) 2023-01-10
JP2023112132A (en) 2023-08-10
US20180125935A1 (en) 2018-05-10
CN108350055A (en) 2018-07-31
CN116063566A (en) 2023-05-05
AU2016331076A1 (en) 2018-04-05
IL295423B2 (en) 2023-11-01
JP2021168699A (en) 2021-10-28
UA126549C2 (en) 2022-11-02
US20180064787A1 (en) 2018-03-08
US10086042B2 (en) 2018-10-02
US20170095531A1 (en) 2017-04-06
SA518391219B1 (en) 2022-11-30
US10493128B2 (en) 2019-12-03
US10183060B2 (en) 2019-01-22
US20200101136A1 (en) 2020-04-02
CA2999280A1 (en) 2017-04-06
SG10201913576RA (en) 2020-02-27
KR20180051651A (en) 2018-05-16
SG11201801984TA (en) 2018-04-27
US20190151413A1 (en) 2019-05-23
IL258029A (en) 2018-05-31
CN116063567A (en) 2023-05-05
US20200246431A1 (en) 2020-08-06
EP3356393A4 (en) 2019-08-07
AU2021200367C1 (en) 2024-05-30
US20200261537A1 (en) 2020-08-20
RU2766200C1 (en) 2022-02-09
US10660936B2 (en) 2020-05-26
AU2021200367A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
HK1258835A1 (en) Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
HK1259190A1 (en) Methods and compositions relating to chimeric antigen receptors
IL282168A (en) Factor viii chimeric proteins and uses thereof
HK1252643A1 (en) Compositions and methods for tcr reprogramming using fusion proteins
HK1253306A1 (en) Anti-ntb-a antibodies and related compositions and methods
ZA201704231B (en) Chimeric protein
SI3240895T1 (en) Compositions and methods for protein glycosylation
GB201709537D0 (en) Fusion protein comprising three binding domains to 5ta and cd3
SG11201704010UA (en) Fibroin-derived protein composition
IL247632A0 (en) Methods and compositions for secretion of heterologous polypeptides
EP3256163A4 (en) Methods and compositions for modulating lilr proteins
IL257302B (en) Apoa-1 fusion polypeptides and related compositions and methods
HK1243107B (en) Chimeric protein